Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Xylitol Chewing Gum Consumption on Coagulation Parameters and Salivary Oral Microbiological Markers in Healthy Young Adults

16. november 2026 oppdatert av: Bezmialem Vakif University

The Effect of Xylitol Consumption on Blood Coagulation Parameters and Oral Microbiological Markers in Saliva in Healthy Young Adults

Xylitol is a natural sweetener that is widely used in chewing gum and oral care products because it helps prevent tooth decay. Some recent studies, mostly in older adults with heart disease or other health conditions, have raised questions about whether xylitol may affect blood clotting. It is not known whether regular, everyday amounts of xylitol have any effect on blood clotting in healthy young people.

This study will look at whether chewing xylitol gum every day for 4 weeks changes blood clotting tests in healthy adults aged 18 to 35 years. It will also look at whether xylitol gum changes the bacteria found in saliva.

Sixty healthy volunteers will be randomly assigned to one of two groups of 30 people each. One group will chew gum containing xylitol (2 pieces, 3 times a day, for a total of 6 grams of xylitol per day). The other group will chew gum that contains sorbitol instead of xylitol, in the same way and for the same length of time. Participants and researchers will know which gum is being used.

Blood and saliva samples will be collected at the start of the study and again after 4 weeks. The blood tests will measure platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer, and thrombin-antithrombin complexes. The saliva samples will be used to study the types and amounts of bacteria in the mouth. Researchers will contact participants every week to ask how they are doing and to record any side effects.

Studieoversikt

Detaljert beskrivelse

Background: Xylitol is a five-carbon sugar alcohol (polyol) that occurs naturally in small amounts in fruits and vegetables. It is widely used as a low-calorie sweetener and, because it helps prevent dental caries, it is commonly added to chewing gum, lozenges and oral care products. In recent years, observational and laboratory studies of some polyol sweeteners, notably erythritol, have suggested links with increased platelet reactivity and thrombotic events. A recent publication reported that high blood levels of xylitol were associated with cardiovascular events in older adults with existing cardiovascular risk factors, and that a single high dose of xylitol (30 g in a drink) increased platelet responsiveness in healthy volunteers over a short period. These findings cannot be directly applied to healthy young adults who use xylitol regularly in everyday amounts, and the effect of repeated daily xylitol intake on blood clotting in this group has not been studied in controlled trials. Xylitol is also known to affect cariogenic bacteria in the mouth, but studies that evaluate systemic clotting markers and the oral microbial profile together are lacking.

Objectives: The primary objective is to evaluate the effect of 4 weeks of daily xylitol chewing gum use on blood coagulation and thrombotic markers in healthy young adults. The secondary objective is to evaluate changes in oral microbiological markers (oral microbiome profile and relative abundance of bacterial species) in saliva.

Study Design: This is a single-center, randomized, open-label, parallel-group, controlled trial conducted at Bezmialem Vakıf University, Faculty of Dentistry, Department of Restorative Dentistry, with blood sampling and laboratory testing performed at the Bezmialem Vakıf University Hospital. Sixty healthy volunteers aged 18 to 35 years are randomly assigned (1:1, computer-based randomization) to a xylitol group (n = 30) or a control group (n = 30). The sample size was calculated using G*Power 3.1 (effect size d = 0.8, alpha = 0.05, power = 0.80), which gave 26 participants per group; 30 per group are enrolled to allow for dropouts. Because the two gums differ in taste and appearance, blinding is not applied.

Intervention: The xylitol group chews gum containing 1 g of xylitol per piece: 2 pieces, 3 times a day, for a total of 6 g of xylitol per day for 4 weeks. The control group chews sorbitol-containing, xylitol-free gum in the same way, with the same frequency and duration. Products are supplied in single-day packs. Participants record their daily gum use in a diary, and use below 80% is defined as non-adherence. During the study, participants must avoid other sweeteners, other chewing gum, polyol-rich products, oral care products that affect the oral flora, probiotics, and nutritional supplements, as well as medicines and herbal products that affect blood clotting.

Study Procedures: At baseline (Day 0), participants receive information, give written informed consent, and are screened by medical history and the eligibility criteria. After an overnight fast of at least 8 hours, a venous blood sample is taken at the hospital laboratory. A saliva sample is collected by a non-invasive method, with participants asked not to eat, drink or chew gum for at least 30 minutes beforehand. Participants then receive their study gum and instructions. Researchers contact participants once a week (telephone, message or in person) to check adherence, concurrent medication and any side effects such as gastrointestinal complaints, allergic reactions, or bleeding- or clotting-related symptoms. At the end of Week 4, blood and saliva sampling is repeated in the same way.

Measurements: Blood: platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and thrombin-antithrombin (TAT) complexes. Saliva: oral microbiome profile and relative abundance of bacterial species. Saliva samples are coded, contain no personal identifiers, and only the microbial content is analyzed; human genome sequences are excluded from analysis.

Statistical Analysis: For each parameter, the change from baseline to Week 4 is calculated and compared between the xylitol and control groups. Normality is tested with the Shapiro-Wilk test. Independent-samples t-test (or Mann-Whitney U test) is used for between-group comparisons, and paired t-test (or Wilcoxon signed-rank test) for within-group comparisons. Repeated-measures ANOVA is used to assess time-by-group interaction where appropriate. Categorical variables are compared with chi-square or Fisher's exact test. Oral microbiome data are summarized by relative abundance and diversity indices (for example, Shannon index), and associations with coagulation markers are examined by correlation analysis. Results are reported with effect sizes and 95% confidence intervals. A two-sided p value below 0.05 is considered statistically significant.

Safety: Xylitol is a food-grade sweetener generally recognized as safe, and the 6 g daily dose is within commonly used consumption levels. Participants are healthy adults with no clotting disorders and no use of anticoagulant or antiplatelet medicines. Participants who develop a serious adverse event, a clinically significant abnormal laboratory result, or a condition requiring prohibited medication are withdrawn and referred for medical care. Participants may leave the study at any time without giving a reason. Personal data are stored under coded identifiers in accordance with Turkish personal data protection law and the Declaration of Helsinki.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 35 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Healthy male or female adults aged 18 to 35 years
  • Body mass index (BMI) 18.5 to 24.9 kg/m²
  • Judged healthy by medical history and clinical evaluation, with no systemic disease (cardiovascular, metabolic, endocrine, hematologic, immune, liver or kidney)
  • No regular medication use, in particular no anticoagulant, antiplatelet, corticosteroid, immunosuppressant or hormonal medicines
  • No use of antibiotics in the last 4 weeks, and no use of antiseptic mouthwash (for example chlorhexidine) in the last 2 weeks
  • Non-smoker, with no regular alcohol or substance use
  • No active oral infection, acute periodontal disease or advanced dental pathology
  • No known allergy to xylitol, sorbitol or other chewing gum ingredients
  • Agrees not to use other chewing gum, sweeteners, oral care products or probiotics during the study
  • Able to attend follow-up contacts and to follow study instructions
  • Has read and signed the written informed consent form

Exclusion Criteria:

  • Chronic systemic disease (for example diabetes, hypertension, coronary artery disease, thyroid disease, hematologic disorder, liver or kidney failure)
  • Coagulation disorder, clotting factor deficiency, or family history of thrombosis
  • Use of anticoagulants, antiplatelets, corticosteroids, immunosuppressants or hormonal medicines, including oral contraceptives
  • Known allergy, intolerance or marked gastrointestinal sensitivity to xylitol, sorbitol, other sugar alcohols or gum ingredients
  • Pregnancy, breastfeeding, or planned pregnancy
  • Systemic antibiotic use in the last 4 weeks, or regular antiseptic mouthwash use (for example chlorhexidine, povidone-iodine) in the last 2 weeks
  • Surgery, blood transfusion, serious infection or hospital stay in the last 3 months
  • Smoking, or regular alcohol or substance use
  • Active periodontal disease, oral infection, oral mucosal lesion or marked gingival bleeding
  • Professional athletes or people who exercise very intensively
  • Wish to use other sweeteners, energy drinks, vitamins or nutritional supplements during the study
  • Psychiatric illness or cognitive impairment that prevents giving informed consent
  • Regular physician supervision or chronic medication use

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Xylitol gum

Participants chew xylitol chewing gum (1 g of xylitol per piece), 2 pieces 3 times a day, for a total of 6 g of xylitol per day for 4 weeks.

Chewing gum containing 1 g of xylitol per piece. Participants chew 2 pieces 3 times a day (6 g of xylitol per day) for 4 weeks.

Aktiv komparator: Sorbitol gum

Participants chew xylitol-free, sorbitol-containing chewing gum, 2 pieces 3 times a day, with the same frequency and duration as the xylitol group, for 4 weeks.

Xylitol-free chewing gum containing sorbitol. Participants chew 2 pieces 3 times a day for 4 weeks, with the same frequency and duration as the xylitol group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in blood coagulation parameters following xylitol consumption
Tidsramme: Baseline and Day 30

Changes in platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and thrombin-antithrombin (TAT) complex levels will be evaluated

Baseline and Day 30

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in relative abundance of bacterial species in saliva
Tidsramme: Baseline and Day 30

Change from baseline to Week 4 in the relative abundance of bacterial species in saliva samples, assessed by oral microbiome analysis

Baseline and Day 30

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juli 2026

Primær fullføring (Antatt)

15. februar 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

16. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere